Any thoughts that the fortunes of public biopharmaceutical companies would change following a sub-par first quarter have been quickly dispelled after the sector chalked up another losing month with the BioWorld Biopharmaceutical index closing down about 2.5 percent that added to its overall 7 percent swoon since the beginning of the year.